(Updates with closing share price in second paragraph.)
Feb. 12 (Bloomberg) -- Redhill Biopharma Ltd. surged the most in almost one month after the Israeli biopharmaceutical company said it received U.S. Food and Drug Administration approval for a clinical trial of its RHB-102 drug.
The shares jumped 2.8 percent, the most since Jan. 19, to 2.201 shekels at the 5 p.m. close in Tel Aviv, giving the company a market value of 113 million shekels ($30 million).
--Editors: Daliah Merzaban, Shanthy Nambiar
To contact the reporter on this story: Shoshanna Solomon in Tel Aviv at email@example.com
To contact the editor responsible for this story: Claudia Maedler at firstname.lastname@example.org